CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation

BACKGROUND: The adoptive transfer of T cells redirected to tumor via chimeric antigen receptors (CARs) has produced clinical benefits for the treatment of hematologic diseases. To extend this approach to breast cancer, we generated CAR T cells directed against mucin1 (MUC1), an aberrantly glycosylat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bajgain, Pradip, Tawinwung, Supannikar, D’Elia, Lindsey, Sukumaran, Sujita, Watanabe, Norihiro, Hoyos, Valentina, Lulla, Premal, Brenner, Malcolm K., Leen, Ann M., Vera, Juan F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944113/
https://www.ncbi.nlm.nih.gov/pubmed/29747685
http://dx.doi.org/10.1186/s40425-018-0347-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944113/
https://www.ncbi.nlm.nih.gov/pubmed/29747685
http://dx.doi.org/10.1186/s40425-018-0347-5

Ejemplares similares